SMNRW — Semnur Pharmaceuticals, Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1913577 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -3,577,000 | -3,633,000 | 2,009,000 | 54,000 | 35,315,000 |
| Jun 2026 | 0 | — | -4,224,000 | -4,347,000 | 1,943,000 | 39,000 | 31,616,000 |
| Mar 2026 | 0 | — | -4,576,000 | -4,576,000 | 1,969,000 | 103,000 | 27,295,000 |
| Dec 2025 | 0 | — | -6,158,000 | -6,158,000 | 1,346,000 | 20,000 | 22,096,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,635,000
Investing CF
—
Financing CF
$10,604,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-288,356,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-18,535,000
Pretax Income TTM
$-18,714,000
Interest Exp TTM
$179,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -160,416,000 | -160,416,000 | 1,346,000 | 22,096,000 | -20,750,000 | -5,867,000 |
| Dec 2024 | 0 | -4,690,000 | -4,690,000 | 6,684,000 | 49,468,000 | -42,784,000 | -4,891,000 |
| Dec 2023 | 0 | -3,261,000 | -3,261,000 | 703,000 | 38,797,000 | -38,094,000 | -1,677,000 |
| Dec 2022 | 0 | -3,765,000 | -3,765,000 | 762,000 | 35,595,000 | -34,833,000 | -4,043,000 |
TTM Snapshot
Revenues TTM
$97,051
NetIncome TTM
$-168,759,275
OpCashFlow TTM
—
Assets (Latest)
$1,943,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.26T | $1415.55 | — |
| JNJ | JOHNSON & JOHNSON | $670.92B | $278.70 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
News headlines (Yahoo Finance, 1h cache)
Recent Insider Activity
No insider activity indexed for this ticker.